Although single-agent activity has been reported for CDK4/6 inhibitors, combinations with other drugs has demonstrated enhanced anti-cancer efficacy, including combination of ribociclib with an aromatase inhibitor as approved as a first-line treatment for postmenopausal women with metastatic HR+/HER2- breast cancer [17]. Here, CDK4 is linked to breast carcinoma.